Tennessee Sandoz Price-Fixing Settlement Reaches $400M

• Sandoz Inc. has reached a $400 million settlement in principle with 43 U.S. states and territories over alleged generic drug price-fixing.
• The agreement resolves claims of widespread conspiracies to manipulate prices, reduce competition, and restrain trade.
• Sandoz also committed to significant internal reforms to strengthen antitrust compliance and promote fair competition.
• The settlement includes allegations against Sandoz's international affiliates, including Novartis AG, for anticompetitive conduct and fraudulent asset transfers.
• This action is part of a broader multistate litigation, initiated in 2016, targeting numerous generic drug manufacturers and executives.

This comprehensive resolution underscores a commitment to protecting consumers and ensuring fair competition within the vital generic drug market, holding companies accountable for unlawful practices.

Sandoz Inc. has reached a significant settlement in principle with a bipartisan coalition of 43 U.S. states and territories, including Tennessee, to resolve long-standing allegations of generic drug price manipulation. Tennessee Attorney General Jonathan Skrmetti announced the agreement, which addresses claims that the pharmaceutical manufacturer engaged in widespread conspiracies to inflate prices, reduce market competition, and restrain trade within the generic drug sector.

The proposed resolution entails a monetary payment of approximately $400 million from Sandoz. However, the company's total financial commitment to resolve these claims, when factoring in previous settlements with other states, is expected to be around $469 million. Beyond the financial terms, the agreement mandates Sandoz to implement substantial internal reforms aimed at bolstering its compliance with antitrust laws and fostering fair competition across its operations. This Tennessee Sandoz price-fixing settlement remains contingent upon securing official signatures from all participating states and territories.

This settlement is a component of a larger, ongoing multistate drug price-fixing litigation that commenced in 2016, spearheaded by the Connecticut Attorney General's Office. The comprehensive legal action alleges that numerous generic drug manufacturers and their executives systematically coordinated efforts to fix prices, allocate markets, and suppress competition, ultimately at the expense of consumers.

The states' cases are built upon years of meticulous investigation, drawing on a vast array of evidence. This includes testimony from cooperating witnesses, an examination of more than 20 million documents, and analysis of millions of phone records. The coalition asserts that these companies orchestrated their anticompetitive activities through various channels, including industry meetings, phone calls, emails, and text messages, all with the intent to artificially inflate drug prices. In related actions within the same litigation, settlements totaling approximately $96.5 million have already been secured from other generic drug manufacturers, including Glenmark, Lannett, Bausch, Apotex, and Heritage, as the coalition prepares for a trial anticipated in 2027.

A critical aspect of the Sandoz generic drug antitrust settlement addresses the alleged involvement of Sandoz's international affiliates. The agreement specifically resolves claims against Novartis AG, Sandoz AG, and Sandoz Group AG, which are past and present international affiliates of Sandoz Inc. These entities were accused not only of participating in the alleged anticompetitive conduct but also of fraudulently transferring assets in an attempt to evade liability.

This inclusion highlights a broader legal strategy to ensure comprehensive accountability across corporate structures, particularly when asset transfers might be used to circumvent financial obligations arising from unlawful activities. The resolution underscores the commitment to pursuing all parties implicated in price manipulation schemes, regardless of their direct operational role within the U.S. market.

Attorney General Jonathan Skrmetti emphasized the fundamental importance of genuine competition in free markets. He stated that when companies conspire to manipulate prices rather than engaging in honest competition, it is Tennessee families who bear the brunt, paying more for essential medications. This perspective underscores the consumer protection focus of the multistate drug price-fixing litigation.

Skrmetti affirmed that the Jonathan Skrmetti Sandoz settlement reflects a steadfast commitment to safeguarding consumers, preserving competitive market dynamics, and holding corporations accountable for legal transgressions. The coalition of states and territories involved in securing this settlement in principle is extensive, encompassing Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, the Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Dakota, the U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. This comprehensive resolution underscores a commitment to protecting consumers and ensuring fair competition within the vital generic drug market, holding companies accountable for unlawful practices.

This settlement signals heightened regulatory scrutiny on generic drug manufacturers, compelling compliance officers to review and strengthen antitrust compliance programs, particularly concerning pricing, market allocation, and affiliate liability for asset transfers. Lawyers should advise clients in this sector on potential exposure and the need for robust internal controls.

Source: Reporting based on a press release from the Tennessee Attorney General's Office.